Latin America Point of Care Diagnostics Market

The Latin America point-of-care diagnostics industry is projected to grow at a CAGR of 7.9% during the forecast period. The market is projected to grow from USD 0.79 billion in 2026 to USD 1.15 billion by 2031. This growth is driven by the rising rates of infectious and chronic diseases in the region. The increasing incidence of infectious diseases, alongside a growing prevalence of cancers and metabolic disorders, is boosting the demand for point-of-care diagnostics in Latin America. Additionally, new government initiatives to improve healthcare infrastructure and enhance primary healthcare facilities are positively influencing the growth of the point-of-care diagnostics industry in this region. Countries such as Brazil, Mexico, and Argentina are making significant contributions to this expansion, as investment in the healthcare sector across Latin America is growing.

In December 2025, Roche received FDA clearance for its rapid Point-of-care Bordetella (Whooping Cough) Molecular Test. The Roche Cobas Liat Point-of-care Test received FDA 510(k) clearance and a CLIA waiver, enabling the detection of Bordetella infections in just 15 minutes.

To know about the assumptions considered for the study download the pdf brochure

In June 2024, Abbott achieved clearances from the US FDA for its over-the-counter continuous glucose monitoring systems, Lingo and Libre Rio, providing patients increased access to glucose monitoring via consumer-friendly options. Built on Abbott's Libre platform, its consumer-friendly device, Lingo, aims to support wellness monitoring, and Libre Rio aims to support adults with type 2 diabetes not requiring insulin therapy, furthering the personal testing and home-monitoring approach for diabetes patients.

Latin America Point-of-care Diagnostics Market Overview:

The Latin America point-of-care diagnostics market is dominated by several national and international players, some of which are Danaher (US), Siemens (Germany), F. Hoffmann-La Roche (Switzerland), Abbott Diagnostics (US), Thermo Fisher Scientific (US), Becton Dickinson and Company (US), EKF Diagnostics (UK), bioMérieux (France), Nova Biomedical (US), Werfen (USA), Trinity Biotech (Ireland), Boditech Med Inc. (South Korea), and SEKISUI Diagnostics (US), among others. These companies are increasing their footprint in Latin America through strategic initiatives such as the launch of technologically advanced, portable PoC devices, strategic partnerships, increased footprint in terms of facilities, and collaborations to meet the healthcare requirements of people in the region, which is contributing directly to the increasing use of technologically advanced PoC diagnostics devices in the region.

Abbott is a major market player in the Latin America point-of-care diagnostics market, due to its comprehensive range of diagnostic systems available for various applications, such as blood screening, immunochemistry, and clinical chemistry systems. Abbott has established a considerable presence in the region, thereby encouraging the adoption of point-of-care diagnostics solutions. The company continues to be a key player in the market due to its focus on research and development, innovation, and the launch of new products, all accompanied by the necessary approvals.

F. Hoffmann-La Roche Ltd. is a well-established name in the global market for diagnostic services and has a strong presence in the Latin America point-of-care diagnostics market. The company’s diverse portfolio of services has enabled it to maintain a competitive edge in this region. Its well-developed distribution networks, both direct and indirect, enable effective market penetration and quick response to market demands. Additionally, F. Hoffmann-La Roche Ltd. employs a balanced strategy that emphasizes both organic and inorganic growth, further strengthening its position in the Latin America point-of-care diagnostics market.

Market Ranking

The Latin America point-of-care diagnostics market comprises a number of key players who have been recognized for their extensive range of testing solutions and drive for technology innovation in the market. Some companies operating in this market include Siemens Healthineers AG (Germany), Abbott (US), Danaher Corporation (US), F. Hoffmann-La Roche (Switzerland), and BD (US), among others. Abbott is well recognized in Latin America for its extensive portfolio of rapid immunoassay and near-patient testing solutions designed to meet the needs of decentralized patient care in this market. Both Siemens and Roche possess competitive advantages in the market through integrated solutions that meet clients’ point-of-care diagnostics requirements, complementing the urgent and routine testing needs of hospitals and clinics in Latin America. Furthermore, Danaher possesses competitive strength through strong recognition in diagnostics, providing solutions that can support clients’ rapid decision-making, while BD recognizes the market with solutions designed to improve the workflow efficiency of clinics in Latin America.

Related Reports:

Latin America Point of Care Diagnostics Market by Product (Glucose, Infectious Disease [TB, HAI, STD], Pregnancy), Purchase Mode (Rx, OTC), Technology (Biochemistry, MDx [RT-PCR, INAAT]), Sample (Blood, Urine), End User (Home Care, Hospitals) - Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com